"Umoja secures $100m to advance CAR-T cell therapy pipeline" was originally created and published by Pharmaceutical ...

India has reached a milestone in cancer treatment with the first successful allogeneic CAR-T therapy at P. D. Hinduja ...

Hinge Bio, Inc., a privately-held biotechnology company, today announced the close of a Series A’ financing led by Point72. Joining Point72 are Ridgeback Capital, InVivium Capital, and Lightswitch ...

UNC Lineberger researchers discovered a three-drug cocktail that enhances the production of T-memory stem cells (TSCMs) in ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on KYTX stock, giving a Buy rating on January 13.Stay Ahead of the ...

For patients with relapsed/refractory large B-cell lymphoma, access to lifesaving CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be limited by post-infusion monitoring protocols ...

Colossal Biosciences announced Wednesday it had reached a $10 billion valuation, putting it in rare “unicorn” territory among Texas startups. The Dallas-based genetic engineering startup landed $200 ...

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center have identified a ...

The Phase 1 GALLOP study evaluating the investigational CAR-T therapy, CB-010, for treatment of lupus nephritis has launched.

在该研究中，陆佩华院长带领团队创新性地采用基于纳米抗体的CD7 CAR-T治疗急性髓系白血病，研究结果不仅在肿瘤杀伤力和安全性上取得了显著进展，更为难治复发急性髓系白血病的治疗开辟了新路径。

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

A study shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer. Investigators examined how molecular dynamics at the immune synapse -- where ...